nach oben

Annals of Hematology

Erschienen in:

04.09.2018 | Original Article

Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?

verfasst von: Mette Vestergaard Elbæk, Anders Lindholm Sørensen, Hans Carl Hasselbalch

Erschienen in: Annals of Hematology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Patients with chronic myelomonocytic leukemia (CMML) have monocytosis and likely a state of chronic inflammation. Both have been associated with an increased risk of atherosclerosis. The aim of the study was to test the hypothesis that CMML patients are at increased risk of developing cardiovascular disease (CVD) due to persistent monocytosis and sustained chronic inflammation. In a retrospective cohort study, we assessed hazards for cardiovascular events after diagnosis in 112 CMML patients and 231 chronic lymphocytic leukemia (CLL) patients. Analyses were carried out on restricted cohorts (CMML = 84, CLL = 186), excluding patients with a prior history of CVD, as well as on unrestricted cohorts. In the restricted cohorts, a significant effect of cardiovascular event occurrence did not remain after adjustment (HR 2.49, 95% CI 0.94–6.60). In unrestricted cohorts, we found a more than twofold increased rate of cardiovascular events in CMML (HR 2.34, 95% CI 1.05–5.20). Our results indicate an increased risk of CVD after the diagnosis in CMML patients.

Orazi A, Bennett JM, Germing U, Brunning RD, Bain BJ, Cazzola M, Foucar K, Thiele J (2017) Chronic myelomonocytic leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (eds) WHO classification of Tumours of Haematopoietic and lymphoid tissues (revised 4th edition). IARCH: Lyon, pp 82–86

Ganda A, Magnusson M, Yvan-Charvet L, Hedblad B, Engstrom G, Ai D, Wang TJ, Gerszten RE, Melander O, Tall AR (2013) Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation 127(9):988–996CrossRefPubMedPubMedCentral

Afiune Neto A, Mansur Ade P, Avakian SD, Gomes EP, Ramires JA (2006) Monocytosis is an independent risk marker for coronary artery disease. Arq Bras Cardiol 86(3):240–244CrossRefPubMed

Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, Mallat Z (2008) Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117(13):1649–1657CrossRefPubMed

Chapman CM, Beilby JP, McQuillan BM, Thompson PL, Hung J (2004) Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke 35(7):1619–1624CrossRefPubMed

Pittet MJ, Swirski FK (2011) Monocytes link atherosclerosis and cancer. Eur J Immunol 41(9):2519–2522CrossRefPubMed

Hasselbalch HC (2012) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119(14):3219–3225CrossRefPubMed

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group (2017) Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131CrossRefPubMed

Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC (2013) Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 12(10):1004–1015CrossRefPubMed

10.

Sherer Y, Shoenfeld Y (2006) Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2(2):99–106CrossRefPubMed

11.

Deniz Peker EP, Pedro Horna, John M. Bennett, Xiaohui Zhang, P.K. Epling-Burnette, Jeffrey E Lancet, Javier Pinilla8, Lynn Moscinski, Alan F. List, Rami S. Komrokji and Ling Zhang. A close association of history of autoimmunity with chronic myelomonocytic leukemia (CMML) in contrast to chronic myelogenous leukemia (CML). 54th ASH annual meeting and exposition; Atlanta 2012

12.

Elbaek MV, Sorensen AL, Hasselbalch HC (2016) Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia? Leukemia Lymphoma:1–7

13.

Alexandrakis M, Coulocheri S, Xylouri I, Ganotakis E, Eliakis P, Karkavitsas N, Eliopoulos GD (1998) Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes. Haematologia 29(1):13–24PubMed

14.

Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ (2007) Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117(1):195–205CrossRefPubMedPubMedCentral

15.

Adamsson Eryd S, Smith JG, Melander O, Hedblad B, Engstrom G (2012) Incidence of coronary events and case fatality rate in relation to blood lymphocyte and neutrophil counts. Arterioscler Thromb Vasc Biol 32(2):533–539CrossRefPubMed

16.

Patnaik MM, Zahid MF, Lasho TL, Finke C, Ketterling RL, Gangat N, Robertson KD, Hanson CA, Tefferi A (2016) Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer J 6(9):e472CrossRefPubMedPubMedCentral

17.

Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL (2017) Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377(2):111–121CrossRefPubMedPubMedCentral

18.

Marty C, Lacout C, Droin N, Le Couedic JP, Ribrag V, Solary E et al (2013) A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 27(11):2187–2195CrossRefPubMed

19.

Zoi K, Cross NC (2015) Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. Int J Hematol 101(3):229–242CrossRefPubMed

20.

Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE (2013) Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol 160(1):70–79CrossRefPubMed

21.

Molenaar RJ, Radivoyevitch T, Sekeres MA, Mukherjee S, Maciejewski JP (2017) High rates of atherosclerotic disease-related mortality in myelodysplastic syndromes and chronic myelomonocytic leukemia patients associated with TET2-mutations. ASH 59th annual meeting & exposition; December 10th Atlanta, GA. Blood:421

22.

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937–951CrossRefPubMed

23.

Lindholm Sorensen A, Hasselbalch HC (2015) Smoking and Philadelphia-negative chronic myeloproliferative neoplasms. Eur J Haematol

24.

Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, Morabito M, Met E, Debord C, Benayoun E, Nloga AM, Fenaux P, Braun T, Willekens C, Quesnel B, Ades L, Fontenay M, Rameau P, Droin N, Koscielny S, Solary E, on behalf of the Groupe Francophone des Myelodysplasies (2015) Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood 125(23):3618–3626CrossRefPubMedPubMedCentral

25.

Yang J, Zhang L, Yu C, Yang XF, Wang H (2014) Monocyte and macrophage differentiation circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomarker Res 2(1):1CrossRef

26.

Idzkowska E, Eljaszewicz A, Miklasz P, Musial WJ, Tycinska AM, Moniuszko M (2015) The role of different monocyte subsets in the pathogenesis of atherosclerosis and acute coronary syndromes. Scand J Immunol 82(3):163–173CrossRefPubMed

27.

Patel BJ, Przychodzen B, Thota S, Radivoyevitch T, Visconte V, Kuzmanovic T, Clemente M, Hirsch C, Morawski A, Souaid R, Saygin C, Nazha A, Demarest B, LaFramboise T, Sakaguchi H, Kojima S, Carraway HE, Ogawa S, Makishima H, Sekeres MA, Maciejewski JP (2017) Genomic determinants of chronic myelomonocytic leukemia. Leukemia 31:2815–2823CrossRefPubMedPubMedCentral

28.

Hanna BS, Ozturk S, Seiffert M (2017) Beyond bystanders: myeloid cells in chronic lymphocytic leukemia. Mol Immunol

29.

Deininger MWN, Tyner JW, Solary E (2017) Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nat Rev Cancer 17(7):425–440CrossRefPubMed

30.

Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, Zhao D, Liu Y, Wang C, Zhang X, Su X, Liu J, Ge W, Levine RL, Li N, Cao X (2015) Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525(7569):389–393CrossRefPubMedPubMedCentral

31.

Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Shimoda H, Marutsuka K, Sashida G, Aoyama K, Yoshimitsu M, Harada T, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K (2015) Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood 125(2):304–315CrossRefPubMed

32.

Tefferi A, Barbui T (2017) Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 92(1):94–108CrossRefPubMed

Titel: Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?
verfasst von: Mette Vestergaard Elbæk
Anders Lindholm Sørensen
Hans Carl Hasselbalch
Publikationsdatum: 04.09.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 1/2019
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3489-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Acute myeloid leukemia with t(19;21)(q13;q22) and marked eosinophilia

Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study

Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient

Cytotoxic T-lymphocyte-associated antigen 4-positive aggressive adult T cell leukemia/lymphoma

Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression